Table 3 Distribution and severity of adverse events in the pediatric allo-HSCT cohort of 42 patients ≤ 100 days post-transplant graded according to CTCAE 4.03.
System | Grade 2–4 N (%) | Grade 3–4 N (%) |
|---|---|---|
All | 189 | 58 |
Cardiac | ||
Hypertension/hypotension | 6 (14) | 0 |
Pericardial effusion | 1 (2) | 0 |
Tachycardia | 1 (2) | 0 |
Dermatology/skin | 11 (26) | 4 (10) |
Epitaxis | 1 (2) | 0 |
Gastrointestinal | ||
Diarrhea | 14 (33) | 6 (14) |
Feeding problems/anorexia | 1 (2) | 0 |
GI bleeding | 4 (10) | 1 (2) |
Nausea/vomiting | 2 (5) | 2 (5) |
Mucositis | 24 (57) | 4 (10) |
General conditions | ||
Anaphylaxis | 1 (2) | 1 (2) |
Edema, weight gain | 10 (24) | 1 (2) |
FUO (prolonged) | 10 (24) | 0 |
Pain | 9 (21) | 2 (5) |
Weight loss | 2 (5) | 1 (2) |
Infections | ||
Local | 10 (24) | 4 (10) |
General | 2 (5) | 2 (5) |
Sepsis/septicemia | 9 (21) | 8 (19) |
Viral reactivation | 17 (40) | 0 |
Laboratory | ||
Bilirubin/liver enzymes | 9 (21) | 6 (14) |
Electrolyte disorder | 3 (7) | 0 |
Hemolysis | 3 (7) | 1 (2) |
Hypoalbuminemia | 1 (2) | 1 (2) |
Thrombocytopenia | 5 (12) | 4 (10) |
Musculoskeletal | 2 (5) | 1 (2) |
Neurology | ||
Ataxia/tremor | 1 (2) | 0 |
Peripheral neuropathy/radiculitis | 1 (2) | 1 (2) |
Seizures | 1 (2) | 1 (2) |
Ocular | 1 (2) | 0 |
Psychiatric | ||
Anxiety, confusion | 2 (5) | 0 |
Pulmonary | 8 (19) | 4 (10) |
Renal/urinary tract | ||
Acute kidney injury | 8 (19) | 1(2) |
Dysuria | 1 (2) | 0 |
Hematuria | 8 (19) | 2 (5) |
